| Help | About | Contact Us

Publication : Mutations of the BRAF gene in human cancer.

First Author	Davies H	Year	2002
Journal	Nature	Volume	417
Issue	6892	Pages	949-54
PubMed ID	12068308	Mgi Jnum	J:77387
Mgi Id	MGI:2181515	Doi	10.1038/nature00766
Citation	Davies H, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-54

abstractText

Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis signalling pathways in which at least one gene is mutated in human cancer. The RAS RAF MEK ERK MAP kinase pathway mediates cellular responses to growth signals. RAS is mutated to an oncogenic form in about 15% of human cancer. The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS. Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers. All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%. Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells. Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation. As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.

Your name:
Your email address:
Subject:
Message:	---- Current page: ---- /mousemine/report.do?id=82604975

MouseMine

Publication : Mutations of the BRAF gene in human cancer.

External Links

Expression

Publication --> Expression annotations

Other

52 Authors

0 Bio Entities

0 Expression